DE3683318D1 - Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege. - Google Patents

Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.

Info

Publication number
DE3683318D1
DE3683318D1 DE8686401001T DE3683318T DE3683318D1 DE 3683318 D1 DE3683318 D1 DE 3683318D1 DE 8686401001 T DE8686401001 T DE 8686401001T DE 3683318 T DE3683318 T DE 3683318T DE 3683318 D1 DE3683318 D1 DE 3683318D1
Authority
DE
Germany
Prior art keywords
alfuzosine
treatment
urinary diseases
urinary
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686401001T
Other languages
English (en)
Inventor
Francois Regnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9319589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3683318(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthelabo SA filed Critical Synthelabo SA
Application granted granted Critical
Publication of DE3683318D1 publication Critical patent/DE3683318D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE8686401001T 1985-05-28 1986-05-12 Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege. Expired - Lifetime DE3683318D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8507950A FR2582513B1 (fr) 1985-05-28 1985-05-28 Compositions pharmaceutiques contenant de l'alfuzosine

Publications (1)

Publication Number Publication Date
DE3683318D1 true DE3683318D1 (de) 1992-02-20

Family

ID=9319589

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686401001T Expired - Lifetime DE3683318D1 (de) 1985-05-28 1986-05-12 Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.

Country Status (12)

Country Link
US (1) US4661491A (de)
EP (1) EP0204597B1 (de)
JP (1) JPS61277620A (de)
AU (1) AU586684B2 (de)
CA (1) CA1261755A (de)
DE (1) DE3683318D1 (de)
DK (1) DK168029B1 (de)
FR (1) FR2582513B1 (de)
HU (1) HUT46221A (de)
IE (1) IE58595B1 (de)
IL (1) IL78934A (de)
ZA (1) ZA863957B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694495B1 (fr) * 1992-08-05 1994-09-23 Synthelabo Préparation pharmaceutique transdermique contenant de l'alfuzosine.
WO1994008040A1 (en) * 1992-09-25 1994-04-14 Synaptic Pharmaceutical Corporation Dna encoding human alpha 1 adrenergic receptors and uses thereof
US5861309A (en) 1992-09-25 1999-01-19 Synaptic Pharmaceutical Corporation DNA endoding human alpha 1 adrenergic receptors
WO1994009371A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
FR2717388B1 (fr) * 1994-03-21 1996-11-22 Synthelabo Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
WO1997017967A1 (en) * 1995-11-15 1997-05-22 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
NZ334018A (en) * 1996-08-29 1999-06-29 Synthelabo Multilayered controlled release tablet comprising a layer of alfuzosin hydrochloride and at least one layer of hydrophillic polymers
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
US5922722A (en) * 1996-11-12 1999-07-13 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6214832B1 (en) 1997-06-18 2001-04-10 Merck & Co., Inc. Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
US6057350A (en) * 1997-06-18 2000-05-02 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6080760A (en) * 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
US6376503B1 (en) 1997-06-18 2002-04-23 Merck & Co., Inc Alpha 1a adrenergic receptor antagonists
US6143750A (en) * 1997-06-18 2000-11-07 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6037354A (en) * 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
WO2000006565A1 (en) 1998-07-30 2000-02-10 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
AU1808400A (en) 1998-10-29 2000-05-22 Merck & Co., Inc. Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
WO2000029386A1 (en) 1998-11-12 2000-05-25 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
GB2355457A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
GB2355263A (en) 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
US20070105880A1 (en) * 2005-11-08 2007-05-10 Torrent Pharmaceuticals Limited Process for the preparation of alfuzosin
US20090069562A1 (en) * 2005-12-26 2009-03-12 Joseph Prabahar Koilpillai Process for the preparation of alfuzosin
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
US20080160081A1 (en) * 2006-12-11 2008-07-03 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making, and methods of use
EP2042179A1 (de) * 2007-09-26 2009-04-01 sanofi-aventis Neue therapeutische Verwendung adrenerger alpha-1-Rezeptorantagonisten
US20100183717A1 (en) * 2009-01-16 2010-07-22 Kristin Arnold Controlled-release formulations
PL2915525T3 (pl) 2011-09-19 2022-01-17 Orexo Ab Tabletki podjęzykowe niepodatne na nadużywanie zawierające buprenorfinę i nalokson
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
CN113599385B (zh) * 2021-08-20 2023-01-03 兰州大学 阿夫唑嗪在制备治疗糖尿病及其并发症药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2466462A2 (fr) * 1978-02-06 1981-04-10 Synthelabo Derives d'alkylenediamines, leur preparation et leur application en therapeutique
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
GB8320958D0 (en) * 1983-08-03 1983-09-07 Pfizer Ltd Quinazoline cardiac stimulants

Also Published As

Publication number Publication date
AU5795186A (en) 1986-12-04
HUT46221A (en) 1988-10-28
IE861395L (en) 1986-11-28
EP0204597A2 (de) 1986-12-10
JPS61277620A (ja) 1986-12-08
CA1261755A (en) 1989-09-26
DK168029B1 (da) 1994-01-24
EP0204597B1 (de) 1992-01-08
FR2582513A1 (fr) 1986-12-05
IE58595B1 (en) 1993-10-20
JPH0564930B2 (de) 1993-09-16
ZA863957B (en) 1987-01-28
DK246586D0 (da) 1986-05-27
EP0204597A3 (en) 1989-08-16
IL78934A (en) 1991-01-31
AU586684B2 (en) 1989-07-20
IL78934A0 (en) 1986-09-30
FR2582513B1 (fr) 1988-08-05
DK246586A (da) 1986-11-29
US4661491A (en) 1987-04-28

Similar Documents

Publication Publication Date Title
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
DE69004081D1 (de) Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
FI874671A (fi) Anordning foer foerhindrande av laeckage i tryckledningar.
DE3584013D1 (de) Zubereitung zur behandlung von psoriasis.
DE3772429D1 (de) Pharmazeutisches praeparat zur behandlung von peridontalkrankheiten.
DE3587741D1 (de) Behandlung von Hautkrankheiten.
DE3685633D1 (de) Behandlung von knochenstoerungen.
DE3878627D1 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
DE3788057D1 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
DE3667605D1 (de) Windel zur verhuetung von wundliegen.
DE3670310D1 (de) Elektrochemische behandlung von ligninen.
DE3782028D1 (de) Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen.
DE3681642D1 (de) Benzopyran-verbindungen zur behandlung von inkontinenz.
DE3687692D1 (de) Geschlechtshormone zur behandlung von immun-mangel-krankheiten.
DE3680507D1 (de) Verwendung von oxirancarbonsaeuren zur behandlung der hyperlipaemie.
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
DE3686019D1 (de) Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten.
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE3686688D1 (de) Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten.
DE3785555D1 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
DE3674321D1 (de) Behandlung geschmeidiger gewebe.
DE3668116D1 (de) Zusammensetzung zur behandlung von infektionen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-SYNTHELABO, PARIS, FR

8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR

8310 Action for declaration of annulment
8313 Request for invalidation rejected/withdrawn
R082 Change of representative

Ref document number: 204597

Country of ref document: EP

Representative=s name: TER MEER STEINMEISTER & PARTNER GBR PATENTANWA, DE